Censo Biotechnologies announces strategic collaboration with Evotec AG to expand iPSC drug discovery
Censo Biotechnologies Ltd. (“Censo”) announced today that it will be collaborating with Evotec AG (Frankfurt Stock Exchange: EVT) to source and provide patient-derived induced pluripotent stem cells (“iPSC”) to support Evotec’s drug discovery iPSC platform.
Censo will provide its sourcing and reprogramming technologies and expertise to create a high-quality, bespoke repository of hundreds of patient-derived iPS cell lines, covering multiple diseases with an initial focus on CNS diseases.
Aidan Courtney, CEO of Censo Biotechnologies, added:
“Both Censo and Evotec believe in the enabling power of patient-derived iPSCs as a drug discovery tool. This collaboration is a validation of Censo’s extensive network, technology platform and expertise in this space. We look forward to working closely with our colleagues at Evotec and supporting their ambitious plans for iPSC-based drug discovery.”
No financial details were disclosed.
About iPSC technology
induced pluripotent stem cell (iPSC) technology makes it possible to create stem cells in the laboratory from any person who donates a skin or blood sample. First pioneered in 2006, the stem cells can be transformed into brain, heart and many other types of cell so that, for stem cells created from individuals suffering from a disease, researchers are then able to replicate the disease under laboratory conditions. This “disease in a dish” research is creating the means to study the early stages of many diseases which was previously not possible.
Censo Biotechnologies Ltd is a stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. The company has the capabilities to generate induced pluripotent stem cells (iPSCs) from large cohorts of individuals and use the potential of these cells to create virtually any cell in the human body. By developing cell-based models of disease using cells from a diverse range of tissue donors, the company supports the development of new targeted treatments for disease. Its major focus is the generation of novel data on drug efficacy and drug response variation for a given population. The company was founded in 2016 through the merger of Roslin Cellab and Roslin Cell Sciences and has facilities in both Edinburgh and Cambridge, UK.